



EMA/492447/2020

Sildenafil ratiopharm

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0046	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	02/09/2020		SmPC, Annex II, Labelling and PL	
IB/0045	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including	11/06/2020	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	replacement or addition)				
IA/0044	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	14/08/2019	n/a		
N/0043	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/01/2019		Labelling and PL	
IB/0042	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	25/10/2018	n/a		
IB/0041/G	This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)	24/07/2018	n/a		
IB/0040/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished	13/04/2018	n/a		

	product - Other variation				
N/0039	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/03/2018		Labelling and PL	
IAIN/0038/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	02/06/2017	n/a		
IB/0037	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	06/01/2016	25/01/2016	SmPC and PL	
IB/0036/G	This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits	23/10/2015	n/a		

	<p>applied during the manufacture of the finished product - Deletion of a non-significant in-process test</p> <p>B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test</p>				
R/0035	Renewal of the marketing authorisation.	24/07/2014	09/09/2014		<p>Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Sildenafil ratiopharm continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Sildenafil ratiopharm continues to be favourable in the treatment of adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Sildenafil ratiopharm to be effective, sexual stimulation is required. The CHMP recommended the renewal of the Marketing Authorisation with unlimited validity.</p>
IB/0033/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes</p>	16/05/2014	09/09/2014	SmPC, Annex II, Labelling and PL	

IAIN/0034	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	28/03/2014	n/a		
IA/0032/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	25/02/2014	n/a		
IB/0031	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	17/10/2013	09/12/2013	SmPC and PL	Update of Section 4.4 of the SmPC to revise the information on acute NAION based on new data coming from the clinical study A1481259 according to the Originator. The package leaflet was amended accordingly.
IB/0030	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	30/08/2013	09/12/2013	SmPC, Labelling and PL	
IA/0029	B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions	03/07/2013	n/a		

IA/0028	B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions	03/07/2013	n/a		
IAIN/0027/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.a.3.a.1 - Changes in the composition (excipients) of the finished product - Changes in components of the flavouring or colouring system - Addition , deletion or replacement C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	13/06/2013	09/12/2013	SmPC, Annex II and PL	
IB/0022/G	This was an application for a group of variations. B.II.a.1.b - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in scoring/break lines intended to divide into equal doses B.II.b.5.z - Change to in-process tests or limits	08/05/2013	09/12/2013	SmPC and PL	

	applied during the manufacture of the finished product - Other variation				
IB/0020/G	This was an application for a group of variations. B.II.a.2.a - Change in the shape or dimensions of the pharmaceutical form - Immediate release tablets, capsules, suppositories and pessaries B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	08/05/2013	09/12/2013	SmPC and PL	
II/0017	To introduce substantial updates to the ASMF for sildenafil citrate, the active substance of Sildenafil ratiopharm. B.I.z - Quality change - Active substance - Other variation	25/04/2013	25/04/2013		
IA/0026/G	This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size	19/04/2013	n/a		

IB/0024	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	17/04/2013	n/a		
IA/0025	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	12/04/2013	n/a		
IB/0023	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	12/04/2013	09/12/2013	SmPC, Labelling and PL	
IB/0019	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	06/03/2013	09/12/2013	SmPC, Annex II and PL	Implementation of changes approved in the reference product - update of section 4.8 to add 'Penile haemorrhage, Haemospermia, and Haematuria' with an uncommon frequency and deletion of the footnote referring to ear disorders as requested by CHMP. The Package Leaflet was updated accordingly. The MAH also took the opportunity to make an editorial change to add the word "anterior" in section 4.4 for some languages and to update Annex II according to the latest QRD template.
IA/0018	B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter	15/01/2013	n/a		
IB/0015	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale	08/01/2013	09/12/2013	SmPC	

	(supported by real time data)				
IAIN/0016/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>B.II.b.2.b.2 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p>	07/12/2012	09/12/2013	Annex II and PL	
IAIN/0014/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding</p>	25/06/2012	n/a		

	manufacturer for batch release)				
N/0013	Update of the local representatives contact details. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/06/2012	09/12/2013	PL	
IA/0012	B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions	14/12/2011	n/a		
IA/0011	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	06/09/2011	n/a		
II/0010	Introduction of a new Pharmacovigilance System (TEVA DDPS Version 10), including a new Qualified person for Pharmacovigilance, which has not been assessed yet by the CHMP for another product of the same MAH. Annex II.b has also been updated with the latest QRD template. C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH	23/06/2011	13/07/2011	Annex II	The MAH has introduced a new pharmacovigilance system used by TEVA Pharmaceutical Industries Ltd., which will be applied for the product Sildenafil Ratiopharm. The detailed description of this pharmacovigilance system includes information pertaining to the qualified person responsible for pharmacovigilance, the global structure of the pharmacovigilance organisation, company procedures relating to pharmacovigilance activities, global safety databases, links with other organisations, training and the quality management system. The MAH has also taken the opportunity to update Annex II.b with the latest wording as per October 2010 CHMP procedural announcement.
IB/0008/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of	28/10/2010	n/a		

	<p>the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting</p>				
--	--	--	--	--	--

	<p>material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p> <p>B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test</p>				
--	--	--	--	--	--

IB/0009	<p>Update of section 4.8 of the Summary of Product Characteristics to include severe cutaneous adverse drug reactions, i.e. Stevens Johnson syndrome and Toxic epidermal necrolysis. The Package Leaflet is amended accordingly. In addition, the web address of the EMA has been updated in Section 10 of the SmPC and in the PL.</p> <p>These changes were made to bring Sildenafil ratiopharm's product information in line with the reference medicinal product Viagra.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH</p>	13/09/2010	n/a	SmPC and PL	
N/0006	<p>Update of the list of local representatives in the Package Leaflet in all EU languages due to the change of the phone number of the local representative in the Netherlands</p> <p>Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)</p>	02/06/2010	n/a	PL	
IA/0007/G	<p>This was an application for a group of variations.</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release</p> <p>A.5.b - Administrative change - Change in the name</p>	12/05/2010	n/a	Annex II and PL	

	and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)				
IA/0005	To add an additional site for secondary packaging B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/05/2010	n/a		
IB/0002/G	This was an application for a group of variations. B.II.a.2.a - Change in the shape or dimensions of the pharmaceutical form - Immediate release tablets, capsules, suppositories and pessaries B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	12/03/2010	n/a	SmPC and PL	
IA/0001/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within	18/02/2010	18/02/2010	SmPC, Labelling and PL	

the range of the currently approved pack sizes